MCID: IDP031
MIFTS: 41

Idiopathic Hypersomnia

Categories: Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Idiopathic Hypersomnia

MalaCards integrated aliases for Idiopathic Hypersomnia:

Name: Idiopathic Hypersomnia 19 58 53 75 33
Primary Hypersomnia 19 71
Disorder of Excessive Somnolence 33
Idiopathic Excessive Sleepiness 58
Hypersomnolence, Idiopathic 71
Idiopathic Hypersomnolence 19
Excessive Somnolence 33
Hypersomnia 33

Characteristics:


Prevelance:

1-5/10000 (Europe) 58

Age Of Onset:

All ages 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 32 F51.1
UMLS via Orphanet 72 C0751757
Orphanet 58 ORPHA33208
SNOMED-CT via HPO 69 271782001 77692006 79519003
ICD11 33 631826564
UMLS 71 C0033138 C0751757

Summaries for Idiopathic Hypersomnia

GARD: 19 Idiopathic hypersomnia (IH) is a neurological sleep disorder that can affect many aspects of a person's life. Symptoms often begin between adolescence and young adulthood and develop over weeks to months. People with IH have a hard time staying awake and alert during the day (chronic excessive daytime sleepiness). They may fall asleep unintentionally or at inappropriate times, interfering with daily functioning. They may also have difficulty waking up from nighttime sleep or daytime naps. Sleeping longer at night does not appear to improve daytime sleepiness. The cause of IH is not known. Some people with IH have other family members with a sleep disorder such as IH or narcolepsy.

MalaCards based summary: Idiopathic Hypersomnia, also known as primary hypersomnia, is related to narcolepsy 1 and narcolepsy 2. An important gene associated with Idiopathic Hypersomnia is HCRT (Hypocretin Neuropeptide Precursor). The drugs Fluticasone and Selegiline have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and breast, and related phenotypes are hypersomnia and excessive daytime somnolence

Orphanet: 58 A rare neurologic disease characterized by an excessive daytime sleepiness with long and unrefreshing naps, and/or prolonged and undisturbed nocturnal sleep, impaired daytime alertness, and/or sleep inertia (ie, great difficulty in waking up after sleep) and where other causes have been excluded.

Wikipedia: 75 Idiopathic hypersomnia (IH) is a neurological disorder which is characterized primarily by excessive... more...

Related Diseases for Idiopathic Hypersomnia

Diseases related to Idiopathic Hypersomnia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 240)
# Related Disease Score Top Affiliating Genes
1 narcolepsy 1 30.9 HLA-DQB1 HCRT
2 narcolepsy 2 30.7 HLA-DQB1 HCRT
3 narcolepsy 30.7 PTGDS HLA-DQB1 HCRT
4 hypersomnia 30.2 PTGDS OPN4 HLA-DQB1 HCRT
5 sleep disorder 30.1 OPN4 HLA-DQB1 HCRT
6 kleine-levin hibernation syndrome 30.0 HLA-DQB1 HCRT
7 neuromyelitis optica 29.9 HLA-DQB1 HCRT
8 recurrent hypersomnia 29.6 HLA-DQB1 HCRT
9 periodic limb movement disorder 29.4 HLA-DQB1 HCRT
10 delayed sleep phase disorder 29.3 OPN4 HCRT
11 guillain-barre syndrome 29.2 HLA-DQB1 HCRT
12 migraine with or without aura 1 29.1 OPN4 HCRT
13 major depressive disorder 11.0
14 dystonia, dopa-responsive, due to sepiapterin reductase deficiency 11.0
15 myotonic dystrophy 2 10.9
16 atypical depressive disorder 10.9
17 bipolar disorder 10.4
18 myotonic dystrophy 1 10.2
19 apnea, obstructive sleep 10.2
20 sleep apnea 10.2
21 obesity-hypoventilation syndrome 10.2
22 bulimia nervosa 10.2
23 cranioectodermal dysplasia 10.1
24 autonomic nervous system disease 10.1
25 encephalitis 10.1
26 encephalopathy 10.1
27 autoimmune disease 10.1
28 central nervous system lymphoma 10.1
29 movement disease 10.1
30 traumatic brain injury 10.1
31 hypothyroidism 10.0
32 mood disorder 10.0
33 rare sleep disorder 10.0
34 prader-willi syndrome 10.0
35 ocular motor apraxia 10.0
36 kearns-sayre syndrome 10.0
37 congenital central hypoventilation syndrome 10.0
38 brain cancer 10.0
39 acute disseminated encephalomyelitis 10.0
40 multiple sclerosis 10.0
41 anxiety 10.0
42 endogenous depression 10.0
43 sjogren syndrome 9.9
44 tatton-brown-rahman syndrome 9.9
45 oppositional defiant disorder 9.9
46 pfeiffer syndrome 9.9
47 alcohol dependence 9.9
48 attention deficit-hyperactivity disorder 9.9
49 oculodentodigital dysplasia 9.9
50 tobacco addiction 9.9

Graphical network of the top 20 diseases related to Idiopathic Hypersomnia:



Diseases related to Idiopathic Hypersomnia

Symptoms & Phenotypes for Idiopathic Hypersomnia

Human phenotypes related to Idiopathic Hypersomnia:

58 30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypersomnia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0100786
2 excessive daytime somnolence 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001262
3 sleep disturbance 58 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Idiopathic Hypersomnia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.1 OPN4
2 Decreased viability GR00381-A-1 9.1 HLA-DQB1 OPN4
3 Decreased viability GR00381-A-3 9.1 HLA-DQB1 OPN4
4 Decreased viability GR00402-S-2 9.1 HLA-DQB1

MGI Mouse Phenotypes related to Idiopathic Hypersomnia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 8.92 HCRT HLA-DQB1 OPN4 PTGDS

Drugs & Therapeutics for Idiopathic Hypersomnia

Drugs for Idiopathic Hypersomnia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
2
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9, 14611-52-0 5195 26757
3
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
4 Sympathomimetics Phase 4
5 Protective Agents Phase 4
6 Hormones Phase 4
7 Psychotropic Drugs Phase 4
8 Antidepressive Agents Phase 4
9 Fluticasone-Salmeterol Drug Combination Phase 4
10 Bronchodilator Agents Phase 4
11 Adrenergic beta-Agonists Phase 4
12 Anti-Asthmatic Agents Phase 4
13 Adrenergic Agonists Phase 4
14 Anti-Allergic Agents Phase 4
15 Xhance Phase 4
16 Hormone Antagonists Phase 4
17 glucocorticoids Phase 4
18 Respiratory System Agents Phase 4
19 Anti-Inflammatory Agents Phase 4
20 Dermatologic Agents Phase 4
21
Salmeterol Xinafoate Phase 4 94749-08-3
22 Neuroprotective Agents Phase 4
23 Antiparkinson Agents Phase 4
24 Monoamine Oxidase Inhibitors Phase 4
25 Neurotransmitter Agents Phase 4
26 Nicotinic Agonists Phase 4
27 Cholinergic Agents Phase 4
28
Dopamine Approved Phase 2, Phase 3 62-31-7, 51-61-6 681
29
Modafinil Approved, Investigational Phase 2, Phase 3 68693-11-8 4236
30
Methylphenidate Approved, Investigational Phase 2, Phase 3 113-45-1 4158
31
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2 23431961
32
Sodium oxybate Approved Phase 3 502-85-2 23663870
33
Esreboxetine Approved, Experimental, Investigational Phase 3 98769-81-4, 71620-89-8, 98819-76-2 65856
34
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
35 Central Nervous System Stimulants Phase 2, Phase 3
36 Dopamine Uptake Inhibitors Phase 2, Phase 3
37 Dopamine Agents Phase 2, Phase 3
38 Anesthetics, Intravenous Phase 3
39 Anesthetics, General Phase 3
40 Anesthetics Phase 3
41 Phosphodiesterase Inhibitors Phase 2, Phase 3
42 Citrate Phase 2, Phase 3
43 Pharmaceutical Solutions Phase 3
44 Adrenergic Agents Phase 3
45
Mirtazapine Approved Phase 2 85650-52-8, 61337-67-5 4205
46
Mazindol Approved, Investigational Phase 2 22232-71-9 4020
47
Flecainide Approved, Withdrawn Phase 2 54143-55-4 3356
48
Dextroamphetamine Approved, Illicit, Investigational Phase 2 51-64-9, 300-62-9 5826 3007
49
Clarithromycin Approved Phase 2 81103-11-9 84029
50
Pentetrazol Experimental, Withdrawn Phase 2 54-95-5

Interventional clinical trials:

(show top 50) (show all 129)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Tolerability of Modafinil for Fatigue and Daytime Sleepiness in Cancer Patients: Preliminary Study Unknown status NCT02385656 Phase 4 Modafinil
2 Double-Blind, Placebo-Controlled, Functional Neuroimaging Study of Armodafinil (200 mg/Day) on Prefrontal Cortical Activation in Patients With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Completed NCT00711516 Phase 4 Armodafinil;Placebo
3 Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function Completed NCT04789174 Phase 4 Solriamfetol;Placebo
4 TITLE: Double-blinded, Double-dummy, Study Comparing Fluticasone-salmeterol to Placebo in Patients With COPD and Associated Poor Sleep or Daytime Somnolence. Completed NCT00731770 Phase 4 Advair 250;Placebo- matched;Placebo;Advair 250 - matched
5 Effect of CPAP on Arterial Hypertension and Cardiovascular Morbi-Mortality in Patients With Sleep Apnea and Without Daytime Sleepiness Completed NCT00127348 Phase 4
6 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Armodafinil Treatment (150 mg) in Improving Clinical Condition Late in the Shift and in Improving Functional and Patient-Reported Outcomes in Adult Patients With Excessive Sleepiness Associated With Shift Work Disorder Completed NCT01080807 Phase 4 Armodafinil;Matching Placebo
7 A Multi-center, Open-Label Study to Evaluate the Efficacy and Safety of Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease Completed NCT04870372 Phase 4 Selegiline
8 A Phase 4, Open-Label, Single-Dose Study to Evaluate Sunosi® (Solriamfetol) Pharmacokinetics in Breast Milk and Plasma of Healthy Postpartum Women Following Oral Administration of Sunosi® Completed NCT05008341 Phase 4 Solriamfetol 150 mg Oral Tablet
9 Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder Recruiting NCT04788953 Phase 4 Solriamfetol Oral Tablet;Placebo
10 Varenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot Study Terminated NCT02473562 Phase 4 Varenicline;Placebo (for varenicline)
11 A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension Completed NCT03533114 Phase 3 JZP-258;Placebo Oral Solution
12 The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study Completed NCT03682185 Phase 3
13 A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects With Narcolepsy Completed NCT02720744 Phase 3 FT218;Placebo
14 A 3-Day, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Armodafinil Treatment (50 and 150 mg/Day) in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder Completed NCT00758498 Phase 3 armodafinil;placebo
15 Caffeine for Excessive Daytime Somnolence in Parkinson's Disease Completed NCT00459420 Phase 2, Phase 3 Caffeine 100-200 mg BID;placebo
16 Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness Completed NCT02739568 Phase 3 Pitolisant (BF2.649);Placebo
17 A Randomised, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38 Week Open Label Extension Phase Completed NCT01066442 Phase 3 BF2.649 (Pitolisant)
18 Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) and Modafinil With Placebo in Treatment of Daytime Sleepiness in Narcolepsy Completed NCT00066170 Phase 3 Xyrem;Xyrem Placebo;Modafinil at established dose;Modafinil (Placebo)
19 Randomized, Double-blind, Placebo and Comparator-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy Completed NCT01638403 Phase 3 BF2.649;Vigil;palcebo
20 BF2.649 in Patients With Obstructive Sleep Apnea Syndrome (OSA) and Treated by Nasal Continuous Positive Airway Pressure (nCPAP), But Still Complaining of Excessive Daytime Sleepiness (EDS) Completed NCT01071876 Phase 3 BF2.649;Placebo
21 Prospective, Randomized, Double-blind Study, Parallel-group, Multi-center Trial Assessing the Effects of Escalating Doses of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolepsy Completed NCT01067235 Phase 3 BF2.649;BF2.649 add on Modafinil
22 A Randomized, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38-Week Open-label Extension Phase Completed NCT01036139 Phase 3 BF2.649 (pitolisant)
23 Prospective, Randomized, Double-blind Study, Placebo-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in Treatment of Excessive Daytime Sleepiness in Narcolepsy Completed NCT01067222 Phase 3 BF2.649;Modafinil;Placebo
24 A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period) Completed NCT00228553 Phase 3 Armodafinil 100 to 250 mg/day
25 A Short-term (8 Week) Open-Label Study, Followed by a Long Term Evaluation, to Assess Patient-Reported Outcomes With Armodafinil Treatment (150 to 250 mg/Day) for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00228566 Phase 3 Armodafinil
26 A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 mg) as Treatment for Adults With Excessive Sleepiness Associated With Chronic Shift Work Sleep Disorder Completed NCT00080288 Phase 3 Armodafinil 150 mg/day;Placebo
27 Efficacy and Safety of BF2.649 in Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea (OSA) Refusing the Nasal Continuous Positive Airway Pressure (nCPAP) Therapy Completed NCT01072968 Phase 3 BF2.649;Placebo
28 An Open-label Naturalistic Pragmatic Study to Assess the Long Term Safety of BF2.649 (Pitolisant) in the Treatment of Excessive Daytime Sleepiness (EDS) in Narcolepsy (12 Months Follow-up, Followed by a Prolonged Follow up) Completed NCT01399606 Phase 3 BF2.649
29 A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia Completed NCT02151253 Phase 2, Phase 3 Armodafinil;Placebo
30 A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy. Completed NCT01800045 Phase 3 Pitolisant;Placebo
31 Phase 2/3 Study of Efficacy and Tolerability of Methylphenidate in the Treatment of Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1 Completed NCT01421992 Phase 2, Phase 3 Methylphenidate;Placebo
32 A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia Recruiting NCT05156047 Phase 3 Pitolisant Oral Tablet;Placebo oral tablet
33 A Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Tolerance of Sodium Oxybate in Patients Affected With Idiopathic Hypersomnia Recruiting NCT03597555 Phase 2, Phase 3 Sodium Oxybate Oral Solution 500 MG/ML;Placebos
34 A Randomized, Double-Blind, Placebo-Controlled, Multi- Center Study to Assess the Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy Recruiting NCT05059223 Phase 3 AXS-12 (reboxetine);Placebo
35 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea Recruiting NCT05223166 Phase 3 Pitolisant;Placebo oral tablet
36 Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR Active, not recruiting NCT04451668 Phase 3 FT218
37 An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 Enrolling by invitation NCT05458128 Phase 3 pitolisant
38 A Study to Assess the Long-term Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy Enrolling by invitation NCT05113745 Phase 3 AXS-12 (reboxetine);Placebo
39 Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness Withdrawn NCT02978651 Phase 3 Pitolisant (BF2.649);Placebo Oral Tablet
40 A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia Unknown status NCT03542851 Phase 2 Pentetrazol (PTZ);Placebo oral capsule
41 Clarithromycin for the Treatment of Hypersomnia Completed NCT01146600 Phase 2 Clarithromycin followed by placebo;Placebo then Clarithromycin
42 A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Completed NCT02512588 Phase 2 BTD-001;Placebo
43 A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors Completed NCT01183312 Phase 1, Phase 2 Flumazenil
44 A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VSF-173 and Matching Placebo in Healthy Male and Female Subjects With Induced Excessive Sleepiness Completed NCT00467441 Phase 2 VSF-173
45 A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Hypnotic Efficacy of EVT 201 in Elderly Patient With Daytime Sleepiness Completed NCT00401284 Phase 2 EVT 201
46 A Phase II, Eight Week, Multi-Center, Open Label Trial of Xyrem(R) (Sodium Oxybate) for Excessive Daytime Sleepiness and Nocturnal Sleep Disturbance in Patients With Mild to Moderate Parkinson's Disease Completed NCT00641186 Phase 2 sodium oxybate
47 A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness in Subjects With Narcolepsy Completed NCT01681121 Phase 2 ADX-N05;Placebo
48 Randomized, Dose-finding Study of BF 2.649 5, 10 20 and 40 mg/d in Comparison to Placebo in Excessive Daytime Sleepiness in Parkinson's Disease Patients (PD) Completed NCT00642928 Phase 2 Placebo;BF 2.649 5 mg;BF 2.649 10 mg;BF 2.649 20 mg;BF 2.649 40 mg
49 A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness Completed NCT03037203 Phase 2 JZP-110
50 Antidepressant Response to a Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder Completed NCT00385437 Phase 2 Mirtazapine Treatment

Search NIH Clinical Center for Idiopathic Hypersomnia

Genetic Tests for Idiopathic Hypersomnia

Anatomical Context for Idiopathic Hypersomnia

Organs/tissues related to Idiopathic Hypersomnia:

MalaCards : Brain, Heart, Breast, Hypothalamus, Thalamus, Prefrontal Cortex, Eye

Publications for Idiopathic Hypersomnia

Articles related to Idiopathic Hypersomnia:

(show top 50) (show all 2205)
# Title Authors PMID Year
1
Body mass index-independent metabolic alterations in narcolepsy with cataplexy. 53 62
19928388 2009
2
Prevalence of the HLA-DQB1*0602 allele in narcolepsy and idiopathic hypersomnia patients seen at a sleep disorders outpatient unit in São Paulo. 53 62
19506770 2009
3
CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. 53 62
19238805 2009
4
DQB1*0301 and DQB1*0601 modulate narcolepsy susceptibility in Koreans. 53 62
17207713 2007
5
CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. 53 62
14638887 2003
6
CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. 53 62
11869432 2002
7
Differentiation of central disorders of hypersomnolence with manual and artificial-intelligence-derived polysomnographic measures. 62
36455881 2022
8
Prevalence of obstructive sleep apnea as assessed by polysomnography in psychiatric patients with sleep-related problems. 62
35029795 2022
9
Associations of somatic depressive symptoms with body mass index, systemic inflammation, and insulin resistance in primary care patients with depression. 62
36074315 2022
10
Clinical considerations for the diagnosis of idiopathic hypersomnia. 62
36401976 2022
11
Association between blood pressure and parameters related to sleep disorders in Tabari cohort population. 62
36376986 2022
12
Central hypersomnia and chronic insomnia: expanding the spectrum of sleep disorders in long COVID syndrome - a prospective cohort study. 62
36352367 2022
13
Symmetrical isolated globus pallidus infarction due to bilateral carotid artery dissection. 62
35915270 2022
14
Sleep outcomes in pediatric mild traumatic brain injury: a systematic review and meta-analysis of prevalence and contributing factors. 62
36413091 2022
15
Central Disorders of Hypersomnolence: Association with Fatigue, Depression and Sleep Inertia Prevailing in Women. 62
36358417 2022
16
Sociodemographic, lifestyle and clinical characteristics of energy-related depression symptoms: A pooled analysis of 13,965 depressed cases in 8 Dutch cohorts. 62
36372132 2022
17
Sleep and Phelan-McDermid Syndrome: Lessons from the International Registry and the scientific literature. 62
35996993 2022
18
Sleep and circadian rhythm profiles in seasonal depression. 62
36244199 2022
19
Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model. 62
36108771 2022
20
Repeated measures of hypocretin-1 in Danish and Italian patients with narcolepsy and in controls. 62
36427467 2022
21
Low carnitine palmitoyltransferase 1 activity is a risk factor for narcolepsy type 1 and other hypersomnia. 62
35810398 2022
22
Socioeconomic status and sleep health: a narrative synthesis of three decades of empirical research. 62
36239056 2022
23
Negative impact of insomnia and daytime sleepiness on quality of life in individuals with the cyclin-dependent kinase-like 5 deficiency disorder. 62
35415902 2022
24
Reader Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study. 62
36253127 2022
25
Editors' Note: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study. 62
36253129 2022
26
Is it time for a gold standard in the diagnosis of hypersomnia? 62
35924659 2022
27
Author Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study. 62
36253130 2022
28
Changes in Sleep Pattern During the COVID-19 Lockdown in Patients With Narcolepsy, Idiopathic Hypersomnia, and Restless Legs Syndrome. 62
35918167 2022
29
Excessive daytime sleepiness: an emerging marker of cardiovascular risk. 62
35102000 2022
30
Central disorders of hypersomnolence: diagnostic discrepancies between military and civilian sleep centers. 62
35855527 2022
31
French Sleepiness Scale for Adolescents-8 items: A discriminant and diagnostic validation. 62
36253180 2022
32
Sleep quality and risk of recurrent aphthous ulcers: A Spanish cohort study. 62
34242451 2022
33
Diabetes, sleep disorders and risk of depression - A Danish register-based cohort study. 62
35932548 2022
34
Pharmacologic Management of Excessive Daytime Sleepiness. 62
36150809 2022
35
Comparison of the efficacy of ultrasound-guided erector spinae plane block and thoracic paravertebral block combined with intercostal nerve block for pain management in video-assisted thoracoscopic surgery: a prospective, randomized, controlled clinical trial. 62
36088297 2022
36
Orexin Receptor Agonists as Possible Treatment for Narcolepsy and Idiopathic Hypersomnia. 62
36105332 2022
37
Precision Medicine for Idiopathic Hypersomnia. 62
36150801 2022
38
Altered Behavioral Responses Show GABA Sensitivity in Muscleblind-Like 2-Deficient Mice: Implications for CNS Symptoms in Myotonic Dystrophy. 62
36150891 2022
39
Sleep disturbances and behavior in Smith-Magenis syndrome. 62
35779287 2022
40
Kleine-Levin syndrome: report of a case with marked dysautonomic features. 62
35393940 2022
41
Proteomic biomarkers of Kleine-Levin syndrome. 62
35859339 2022
42
Leigh-Like Syndrome With a Novel, Complex Phenotype Due to m.10191T>C in Mt-ND3. 62
36249637 2022
43
Understanding and approaching excessive daytime sleepiness. 62
36115367 2022
44
Sleepiness in obstructive sleep apnea using hypopneas defined by a 3% oxygen desaturation or arousal but not by 4% or greater oxygen desaturation. 62
34564819 2022
45
Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort. 62
35750949 2022
46
Sleep disorders in children with asthma. 62
33647191 2022
47
Usefulness of the maintenance of wakefulness test in central disorders of hypersomnolence: a scoping review. 62
35429267 2022
48
Parental burnout and sleep problems in Iranian mothers of primary school-aged children: Exploring the mediation effect of emotional schemas. 62
35849708 2022
49
[Cognitive disorders and sleep disturbances in long COVID]. 62
35576015 2022
50
[Diagnostic strategy for hypersomnolence disorders]. 62
35184867 2022

Variations for Idiopathic Hypersomnia

Expression for Idiopathic Hypersomnia

Search GEO for disease gene expression data for Idiopathic Hypersomnia.

Pathways for Idiopathic Hypersomnia

GO Terms for Idiopathic Hypersomnia

Cellular components related to Idiopathic Hypersomnia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 rough endoplasmic reticulum GO:0005791 8.92 PTGDS HCRT

Sources for Idiopathic Hypersomnia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....